Core Viewpoint - Medicus Pharma Ltd. has appointed Carolyn Bonner as Chief Financial Officer in addition to her role as President, ensuring continuity and stability during the transition following the resignation of the previous CFO due to health reasons [1][2] Leadership Changes - Carolyn Bonner has been serving as Acting Chief Financial Officer since September 12, 2025, and her formal appointment aims to enhance operational and financial integration under a single leader [1][2] - Dr. Raza Bokhari, Executive Chairman & CEO, expressed gratitude to the departing CFO, Jim Quinlan, for his critical role in the company's founding and initial public offering [2] Experience and Background - Carolyn Bonner brings nearly 20 years of experience in healthcare and life sciences, previously serving as President & CEO of PCL, Inc., and holding roles in business development at Rosetta Genomics Ltd. and Inform Diagnostics, Inc. [3][4] Expanded Responsibilities - In her dual role, Bonner will oversee financial reporting, capital markets strategy, budgeting, forecasting, and lead strategic planning across clinical and corporate development initiatives [5] Clinical Development Programs - Medicus is conducting a Phase 2 clinical study (SKNJCT-003) for a novel treatment of basal cell carcinoma (BCC) using dissolvable doxorubicin-containing microneedle arrays, with positive interim results showing over 60% clinical clearance [6][7] - The company has received positive FDA feedback regarding its regulatory pathway for the development of SkinJect, indicating potential for further advancement [7] International Expansion - The company has initiated a clinical study (SKNJCT-004) in the UAE, with plans to randomize 36 patients across six sites, and has received regulatory approvals in the UK to expand its ongoing Phase 2 study [8][10][26] Strategic Collaborations - Medicus entered a non-binding memorandum of understanding with Helix Nanotechnologies to explore co-development of thermostable infectious disease vaccines [11][19] - A strategic collaboration with the Gorlin Syndrome Alliance aims to provide expanded access to SkinJect for patients with Gorlin Syndrome, focusing on real-world data collection for future regulatory filings [14][25] Pipeline Expansion - The acquisition of Antev Limited, a UK-based biotech company, enhances Medicus's pipeline with Teverelix, a next-generation GnRH antagonist for advanced prostate cancer patients [12][20] - Teverelix has shown promising results in clinical trials, with a Phase 2a study achieving a 97.5% probability of testosterone suppression [22][23]

Core Viewpoint - Medicus Pharma Ltd. is actively engaging in clinical development for innovative treatments in oncology and urology, with significant upcoming events and ongoing studies that may impact its market position and growth potential [1][6]. Group 1: Company Events - Medicus Pharma Ltd. will participate in the BTIG Virtual Biotech Conference 2025, with Dr. Raza Bokhari, Executive Chairman and CEO, scheduled for a Fireside Chat on July 30, 2025, at 9:20 a.m. ET [1][2]. - The Fireside Chat will be livestreamed for registered investors, and a recording will be available post-event [2]. Group 2: Clinical Development - The company's lead asset, SkinJect Inc., is focused on a novel treatment for non-melanoma skin cancer, particularly basal cell carcinoma (BCC), utilizing a patented dissolvable doxorubicin-containing microneedle array (D-MNA) [3][9]. - A Phase 2 clinical study (SKNJCT-003) is currently underway across nine clinical sites in the U.S., with an interim analysis showing over 60% clinical clearance after randomizing more than 50% of the targeted 60 patients [4]. - The investigational review board has increased the participant count for SKNJCT-003 to 90 subjects, and the company is also expanding clinical trial sites into Europe [4]. - A separate clinical study (SKNJCT-004) is being conducted in the UAE, randomizing 36 patients across four sites, with Cleveland Clinic Abu Dhabi as the principal investigator [5]. Group 3: Strategic Acquisitions - In June 2025, Medicus Pharma Ltd. announced a definitive agreement to acquire Antev Ltd., a UK-based clinical stage biotech company developing Teverelix for advanced prostate cancer patients [6][10]. - The acquisition is expected to close before the end of August 2025, subject to certain conditions including shareholder approval [6][10].